AMPK-mediated Autophagy is Involved in the Protective Effect of Canagliflozin in the Vitamin D3 Plus Nicotine Calcification Model in Rats

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2023 Jul 31

PMID 37522915

Authors

Wafaa A Hewedy

Shaymaa A Abdulmalek

Doaa A Ghareeb

Esraa S Habiba

Affiliations

Soon will be listed here.

Abstract

Vascular calcification (VC) is a major risk factor for cardiovascular events. A mutual interplay between inflammation, oxidative stress, apoptosis, and autophagy is implicated in its development. Herein, we aimed to evaluate the potential protective effects of canagliflozin in a vitamin D3 plus nicotine (VDN) model of VC, and to explore potential mechanisms. VC was induced by VDN in adult male Wistar rats on day one. Then, rats were randomly assigned into three groups to receive canagliflozin (10 mg or 20 mg/kg/day) or its vehicle for 4 weeks. Age-matched normal rats served as a control group. After euthanization, aorta and kidneys were harvested for biochemical and histopathological evaluation of calcification. Aortic markers of oxidative stress, alkaline phosphatase (ALP) activity, runt-related transcription factor (Runx2) and bone morphogenic protein-2 (BMP-2) levels were determined. Additionally, the protein expression of autophagic markers, LC3 and p62, and adenosine monophosphate activated protein kinase (AMPK) were also assessed in aortic homogenates. Canagliflozin dose-dependently improved renal function, enhanced the antioxidant capacity of aortic tissues and reduced calcium deposition in rat aortas and kidneys. Both doses of canagliflozin attenuated ALP and osteogenic markers while augmented the expression of autophagic markers and AMPK. Histopathological examination of aortas and kidneys by H&E and Von Kossa stain further support the beneficial effect of canagliflozin. Canagliflozin could alleviate VDN-induced vascular calcification, in a dose dependent manner, via its antioxidant effect and modulation of autophagy. Further studies are needed to verify whether this effect is a member or a class effect.

Citing Articles

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases.

Pham L, Mangmool S, Parichatikanond W ACS Pharmacol Transl Sci. 2024; 7(11):3279-3298.

PMID: 39539254 PMC: 11555527. DOI: 10.1021/acsptsci.4c00240.

Targeting the Sirtuin-1/PPAR-Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson's Disease.

Elkady M, Kabel A, Dawood L, Helal A, Borg H, Atia H Medicina (Kaunas). 2024; 60(10).

PMID: 39459469 PMC: 11509249. DOI: 10.3390/medicina60101682.

References

Lin M, Chen T, Leaf E, Speer M, Giachelli C . Runx2 Expression in Smooth Muscle Cells Is Required for Arterial Medial Calcification in Mice. Am J Pathol. 2015; 185(7):1958-69. PMC: 4484217. DOI: 10.1016/j.ajpath.2015.03.020. View

Wu M, Rementer C, Giachelli C . Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int. 2013; 93(4):365-73. PMC: 3714357. DOI: 10.1007/s00223-013-9712-z. View

Lee S, Lee I, Jeon J . Vascular Calcification-New Insights Into Its Mechanism. Int J Mol Sci. 2020; 21(8). PMC: 7216228. DOI: 10.3390/ijms21082685. View

Cao X, Li H, Tao H, Wu N, Yu L, Zhang D . Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway. Endocrinology. 2013; 154(10):3680-9. DOI: 10.1210/en.2013-1002. View

Watanabe S, Fujii H, Kono K, Watanabe K, Goto S, Nishi S . Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus. Sci Rep. 2020; 10(1):20708. PMC: 7693179. DOI: 10.1038/s41598-020-76838-0. View

Cui L, Li Z, Chang X, Cong G, Hao L . Quercetin attenuates vascular calcification by inhibiting oxidative stress and mitochondrial fission. Vascul Pharmacol. 2016; 88:21-29. DOI: 10.1016/j.vph.2016.11.006. View

Takata T, Isomoto H . Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. Int J Mol Sci. 2021; 22(9). PMC: 8122753. DOI: 10.3390/ijms22094374. View

Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis C, Polkinghorne M . Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021; 42(48):4947-4960. PMC: 8691807. DOI: 10.1093/eurheartj/ehab420. View

Mulcahy Levy J, Towers C, Thorburn A . Targeting autophagy in cancer. Nat Rev Cancer. 2017; 17(9):528-542. PMC: 5975367. DOI: 10.1038/nrc.2017.53. View

10.

Hasan R, Lasker S, Hasan A, Zerin F, Zamila M, Parvez F . Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model. Sci Rep. 2020; 10(1):14659. PMC: 7474058. DOI: 10.1038/s41598-020-71599-2. View

11.

Hawley S, Ford R, Smith B, Gowans G, Mancini S, Pitt R . The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels. Diabetes. 2016; 65(9):2784-94. PMC: 5689380. DOI: 10.2337/db16-0058. View

12.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

13.

Niu Y, Zhang Y, Zhang W, Lu J, Chen Y, Hao W . Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1. Front Pharmacol. 2022; 13:820541. PMC: 8996145. DOI: 10.3389/fphar.2022.820541. View

14.

Shen J, Zhao M, Zhang C, Sun X . IL-1β in atherosclerotic vascular calcification: From bench to bedside. Int J Biol Sci. 2021; 17(15):4353-4364. PMC: 8579452. DOI: 10.7150/ijbs.66537. View

15.

Fukushima K, Kitamura S, Tsuji K, Wada J . Sodium-Glucose Cotransporter 2 Inhibitors Work as a "Regulator" of Autophagic Activity in Overnutrition Diseases. Front Pharmacol. 2021; 12:761842. PMC: 8566701. DOI: 10.3389/fphar.2021.761842. View

16.

Cai J, Pardali E, Sanchez-Duffhues G, Ten Dijke P . BMP signaling in vascular diseases. FEBS Lett. 2012; 586(14):1993-2002. DOI: 10.1016/j.febslet.2012.04.030. View

17.

Yoshiyama S, Chen Z, Okagaki T, Kohama K, Nasu-Kawaharada R, Izumi T . Nicotine exposure alters human vascular smooth muscle cell phenotype from a contractile to a synthetic type. Atherosclerosis. 2014; 237(2):464-70. DOI: 10.1016/j.atherosclerosis.2014.10.019. View

18.

Aragon-Herrera A, Feijoo-Bandin S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J . Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019; 170:113677. DOI: 10.1016/j.bcp.2019.113677. View

19.

Moors T, Hoozemans J, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin M . Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener. 2017; 12(1):11. PMC: 5267440. DOI: 10.1186/s13024-017-0154-3. View

20.

Park C, Lee B, Han M, Rhee W, Kwak M, Yoo T . Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. Cell Death Discov. 2022; 8(1):12. PMC: 8748642. DOI: 10.1038/s41420-021-00801-9. View